Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKanlıöz, Murat
dc.contributor.authorEkici, Uğur
dc.date.accessioned2020-08-05T20:05:06Z
dc.date.available2020-08-05T20:05:06Z
dc.date.issued2020en_US
dc.identifier.issn0960-8923
dc.identifier.issn1708-0428
dc.identifier.urihttps://hdl.handle.net/11363/2338
dc.descriptionDocument Information Language:English Accession Number: WOS:000532631600003 PubMed ID: 32405906en_US
dc.description.abstractPurpose To analyze how considering the structure of normotonic pylorus (NP) or hypotonic pylorus (HP) contributes to treatment success in patients administered gastric botulinum toxin A for weight loss. Materials and Methods We measured body mass indexes (BMIs) of the patients who applied for gastric botulinum toxin A (BTA) for weight loss, before and 6 months after the procedure. The patients' pylori were classified as normotonic pylorus (NP) if, during endoscopy, they had a normal peristaltic motion and was closing completely, and as hypotonic pylorus if they were not closing properly or were aperistaltic. We compared the patients' mean pre-operative and 6-month post-operative BMIs. The groups were compared using the chi-square test where a p < 0.05 was considered significant. Results The study included 178 patients administered gastric BTA. In the assessment made without considering the pyloric structure, the mean BMI decreased from 34.76 +/- 7.65 to 33.09 +/- 7.80 kg/m(2), while the difference was not statistically significant (p < 0.06). Conversely, in the analysis performed considering the structure of pylorus, the mean pre-operative BMI of the 45 patients with HP structure was 35.16 +/- 7.07 kg/m(2) which decreased to 35.11 +/- 7.03 kg/m(2) 6 months after the procedure; hence, the difference was not statistically significant (p < 0.7). The mean pre-operative BMI of the 133 patients with NP structure, 34.63 +/- 7.84 kg/m(2), decreased to 32.40 +/- 8.05 kg/m(2) 6 months after the procedure and the difference was statistically significant (p < 0.05)*. Conclusion We advise to be selective in BTA administration and to administer BTA to the patients who, endoscopically, have a NP structure.en_US
dc.language.isoengen_US
dc.publisherSPRINGER, ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATESen_US
dc.relation.isversionof10.1007/s11695-020-04556-7en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectNormotonic pylorusen_US
dc.subjectHypotonic pylorusen_US
dc.subjectGastric Botoxen_US
dc.subjectObesityen_US
dc.subjectINTRAGASTRIC INJECTIONen_US
dc.subjectMIDAZOLAMen_US
dc.titleHow Taking into Account the Pyloric Tonus Contributes to Treatment Success While Administering Gastric "Botulinum Toxin A" for Weight Lossen_US
dc.typearticleen_US
dc.relation.ispartofOBESITY SURGERYen_US
dc.departmentSağlık Bilimleri Yüksekokuluen_US
dc.authoridhttps://orcid.org/0000-0003-4271-184Xen_US
dc.authoridhttps://orcid.org/0000-0002-2660-3120en_US
dc.identifier.volume30en_US
dc.identifier.issue9en_US
dc.identifier.startpage3365en_US
dc.identifier.endpage3369en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess